Previous 10 | Next 10 |
Northwest Biotherapeutics Announces Data Lock of Phase III Trial PR Newswire BETHESDA, Md., Oct. 5, 2020 BETHESDA, Md. , Oct. 5, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® perso...
Executed and closed on August 28, 2020, Northwest Biotherapeutics ( OTCQB:NWBO +5.4% ) acquired Flaskworks, a developer of breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax, for $4.3M. More news on: Northwest Biotherapeutics, Inc....
BETHESDA, Md. , Sept. 1, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the Company has acquired Flaskworks, a company that has devel...
BETHESDA, Md. , Aug. 27, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the Company is pursuing an intensive program of manufacturing...
Northwest Biotherapeutics ( OTCQB:NWBO +2.0% ) has completed a non-dilutive debt financing for net proceeds of additional $5M, via a 21-month note for $5.5M at an 8% annualized interest rate, with no payments due for the first 7 months. More news on: Northwest Biotherapeutics...
BETHESDA, Md. , Aug. 21, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a non-dilutive debt financing for net pr...
BETHESDA, Md. , Aug. 19, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company's ...
Northwest Biotherapeutics ( OTCQB:NWBO -2.9% ) has completed a financing of ~$8M, including ~$7M from offering at $0.32/share of new shares of ~21.8M shares with warrants averaging 21%, exercisable at $0.34 for ~5.3M shares, with an exercise period ranging from 18 to 30 months, and ...
Northwest Biotherapeutics ( OTCQB:NWBO ) : Q2 GAAP EPS of -$0.08. More news on: Northwest Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BETHESDA, Md. , Aug. 11, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for a...
News, Short Squeeze, Breakout and More Instantly...
Northwest Biotherapeutics Inc. Company Name:
NWBO Stock Symbol:
OTCMKTS Market:
Northwest Biotherapeutics Inc. Website:
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities PR Newswire Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes BETHESDA, Md. , July 3, 2024 /PRNewswire/ -- No...
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property PR Newswire Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...